NEW YORK — Proteomics firm Seer said today that it has signed a pair of non-exclusive commercial agreements with Bruker and Thermo Fisher Scientific.
Under the agreements, Seer will be able to offers its Proteograph Product Suite for sale with Bruker's timsTOF Pro mass spectrometer and Thermo Fisher's Orbitrap Eclipse Tribrid and Exploris 480 instruments.
Seer's Proteograph system uses nanoparticle-based enrichment of proteins in samples like human plasma to enable deeper proteomic discovery experiments at high throughput. The technology is based on the observation that when incubated in a biological sample nanoparticles collect proteins, which form a "corona." Given this, nanoparticles can serve as an enrichment tool, allowing researchers to pull proteins out of a sample, which they can then identify and quantify using technologies like mass spec.
Mitch Kennedy, president of chromatography and mass spectrometry at Thermo Fisher Scientific, said in a statement that the combination of the Orbitrap platforms with Seer's Proteograph Product Suite "will equip current customers with new capabilities to drive their studies and will simplify adoption of proteomics among new customers who are looking to complement their genomics and scalable multi-omics capabilities."
"We are excited to partner with Seer to advance unbiased, deep proteomics at scale, leveraging unique and innovative features of our timsTOF Pro to enable high-throughput, translational studies requiring depth of coverage and label-free quantitation," said Rohan Thakur, Bruker Daltonics EVP of life-science mass spectrometry.